ストックスクリーナーアプリを入手
0.2665
0.19%
-0.0005
プレマーケット:
.30
0.0335
+12.57%
前日終値:
$0.267
開ける：
$0.28
24時間の取引高:
1.02M
Relative Volume:
0.47
時価総額：
$32.73M
収益：
$1.29M
当期純損益:
$-29.87M
株価収益率:
-0.7403
EPS:
-0.36
ネットキャッシュフロー:
$-14.70M
1週間 パフォーマンス:
-16.17%
1か月 パフォーマンス:
+6.60%
6か月 パフォーマンス:
-64.47%
1年 パフォーマンス:
-53.87%
1日の値動き範囲:
$0.26
$0.285
1週間の範囲:
$0.26
$0.3268
52週間の値動き範囲:
$0.22
$0.94
VolitionRX Ltd Stock (VNRX) Company Profile
名前
VolitionRX Ltd
セクター
電話
646 650 1351
住所
No. 24-05 Shaw Centre, 1 Scotts Road, Singapore, TX
VNRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VNRX
VolitionRX Ltd
|
0.2665 | 32.79M | 1.29M | -29.87M | -14.70M | -0.36 |
|
TMO
Thermo Fisher Scientific Inc
|
623.91 | 235.43B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
235.75 | 167.20B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
694.75 | 55.72B | 4.17B | 1.03B | 940.22M | 12.61 |
|
IQV
Iqvia Holdings Inc
|
241.04 | 40.77B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
135.95 | 38.46B | 6.95B | 1.30B | 1.15B | 4.5696 |
VolitionRX Ltd Stock (VNRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-08 | 開始されました | H.C. Wainwright | Buy |
| 2023-02-01 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2022-02-17 | 再開されました | Cantor Fitzgerald | Overweight |
| 2021-03-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-05-16 | 開始されました | Maxim Group | Buy |
| 2018-05-14 | 繰り返されました | The Benchmark Company | Buy |
| 2016-09-07 | 繰り返されました | Rodman & Renshaw | Buy |
| 2016-02-01 | 開始されました | Rodman & Renshaw | Buy |
すべてを表示
VolitionRX Ltd (VNRX) 最新ニュース
Aug Wrap: Is VolitionRx Limited benefiting from innovation trendsMarket Activity Report & Growth Focused Stock Pick Reports - baoquankhu1.vn
VNRX: D. Boral Capital Maintains Buy Rating and $3 Price Target - GuruFocus
VolitionRx (VNRX) Expands Nu.Q Vet Cancer Test Reach in U.S. and Asia - GuruFocus
Dog cancer blood test expands to all 50 states and parts of Asia - Stock Titan
VolitionRX (VNRX) Receives Buy Rating, Price Target Maintained a - GuruFocus
Why VolitionRx Limited stock is popular among millennialsEarnings Growth Report & Expert Curated Trade Setups - Улправда
Volitionrx stock soars after feline cancer test shows high accuracy By Investing.com - Investing.com Australia
VolitionRx Signs Amended Securities Purchase Agreement With Lind Global Asset Management XII - TradingView — Track All Markets
Is VolitionRx Limited stock trading near support levels2025 Key Lessons & Growth Oriented Trading Recommendations - Улправда
VolitionRx Limited Announces Breakthrough Clinical Data for Nu.Q Vet Cancer Test in Cats - marketscreener.com
VolitionRx secures $2 million in additional funding through convertible note By Investing.com - Investing.com India
VolitionRX announces breakthrough clinical data for Nu.Q® veterinary cancer test in cats - MarketScreener
VolitionRx secures $2M financing through amended securities agreement; shares up - MSN
VolitionRX Ltd enters amended securities purchase agreement - marketscreener.com
VolitionRx Secures $2.0 Million in Funding - Yahoo Finance
VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats - marketscreener.com
A simple blood test that can spot lymphoma in cats may be on the way - Stock Titan
VolitionRx downgraded to Hold from Buy at Maxim - MSN
How buybacks impact VolitionRx Limited stock valueJuly 2025 Update & Entry and Exit Point Strategies - Улправда
How VolitionRx Limited stock performs during Fed tightening cyclesJuly 2025 Pullbacks & Fast Gain Swing Trade Alerts - Улправда
VolitionRX (VNRX) Target Price Slashed by D. Boral Capital | VNR - GuruFocus
Simple blood tests for cancer and sepsis move closer to hospitals in 2025 - Stock Titan
VolitionRx announces new paper on Capture-Seq, achieves 180-fold enrichment - MSN
VolitionRx to eliminate veterinary CEO role as part of cost-realignment - Investing.com Australia
VolitionRx Announces Termination of CEO Position at Subsidiary - TradingView — Track All Markets
VolitionRx (VNRX) to end Volition Veterinary CEO role, retain Dr. Butera as consultant - Stock Titan
VolitionRx (VNRX) Unveils Innovative Cancer Detection Method - GuruFocus
Volition (NYSE AMERICAN: VNRX) posts 100% sensitivity in 70-person liquid biopsy study - Stock Titan
VolitionRx’s (VNRX) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
Why VolitionRX Limited stock is a strong buy call2025 Pullback Review & Risk Controlled Daily Plans - Newser
VolitionRx’s Sepsis Biomarker Selected for French National Healthcare Initiative - citybuzz
VolitionRX (VNRX): Analyst Maintains 'Buy' Rating Amidst Stable Price Target | VNRX Stock News - GuruFocus
VolitionRx (NYSE AMERICAN: VNRX) named sole biomarker partner in €6.3M DETECSEPS sepsis detection program - Stock Titan
How VolitionRx Limited stock valuations compare to rivalsGap Up & Fast Entry Momentum Trade Alerts - Newser
VolitionRx (NYSE:VNRX) Lowered to “Hold” Rating by Maxim Group - Defense World
How VolitionRx Limited stock reacts to job market data2025 Market Sentiment & Consistent Growth Equity Picks - Newser
VNRX: Maxim Group Downgrades VolitionRX to Hold | VNRX Stock New - GuruFocus
Healthy Upside Potential: VolitionRX Ltd (VNRX) - Setenews
VolitionRx (VNRX) Insider Trading Activity 2025 - MarketBeat
Why millennials buy VolitionRX Limited stockQuarterly Earnings Summary & AI Optimized Trade Strategies - moha.gov.vn
VolitionRX (VNRX) Analyst Rating Update: Maintain 'Buy' with $5 Target | VNRX Stock News - GuruFocus
VolitionRX Ltd (VNRX) is looking forward to a strong quarter - Setenews
VolitionRx (VNRX) Stock Surges with First Sale of Nu.Q Cancer Assays to European Cancer Center - parameter.io
VolitionRx announces first sale of Nu.Q Cancer assays to French hospital - Investing.com India
VolitionRx announces first sale of Nu.Q Cancer assays to French hospital By Investing.com - Investing.com South Africa
Nu.Q Cancer Assays Sold for Certification at Lyon Center, VolitionRx (NYSE: VNRX) - Stock Titan
Freedom Capital Markets lowers VolitionRX stock price target on delayed revenue growth - Investing.com Australia
Freedom Capital Markets lowers VolitionRX stock price target on delayed revenue growth By Investing.com - Investing.com South Africa
Can VolitionRX Limited stock sustain breakout momentumEarnings Risk Report & Stepwise Trade Execution Plans - newser.com
Will VolitionRX Limited stock beat international competitionQuarterly Earnings Summary & Capital Efficient Trading Techniques - newser.com
What makes VolitionRx Limited stock attractive to growth fundsJuly 2025 Retail & Accurate Trade Setup Notifications - newser.com
VolitionRX Ltd (VNRX) 財務データ
収益
当期純利益
現金流量
EPS
1.40%
0.21%
大文字化:
|
ボリューム (24 時間):